✔ 2024 we were awarded the first prize for innovation in a TV contest based on the Shark Tank show.

✔ 2024 Working with UNIVO IRB, UNIVO is compliant with regulations that relate to the protection of research participants within the Code of Federal Regulations (CFR).​

✔ 2023 The  Israel Innovation Authority (IIA) chose us to participate in the Singapore-Israeli delegation.

​

​

​position

✔ Won a contest by Vision-Elements (AI).

✔ Clinical trial with over 500 lesions, and more than 13,000 measurements.

✔ Regulatory strategy By Duet Medical and GSAP.

✔ Patent, at a national stage and after IDS (Information Disclosure Statement) in November 2024. 

✔ New PatScope Scanner (MVP, trl6).

✔ Business plan. Business model.

✔ Conference presentations.

✔ Proposal to Space Agency to investigate astronaut's skin degradation under microgravity conditions.

​

market

• Clinics and centers, Dermatologists, General practitioners (GPs), Beauticians, and home users. 

• The TAM is greater than $1 billion USD, and growing rapidly with a CAGR > 10%.

• We have attracted and are increasingly continuing to attract Clinics, worldwide.
• ​

business model

• Sales - of the scanner as standalone unit and as adapter for smartphones.

• AI - for lesion distortion as decision support.

• Telemedicine - our dermatologists will assist with follow-ups.

• Reimbursement - following CPT code similar to x-ray, CT, and MRI.

​

current activities
• We are in preliminary planning for the development of the next generation of the PatScope.

• Submitting a pre-submission to the FDA to confirm the regulatory pathway we built with Duet Medical and GSAP as control and re-examination. Design clinical trials according to the FDA's answer to the Pre-Sub. Exception of Brand Designation.

• Market survey to better define the scanner's positioning.

• Expansion of experiments in hospitals.

• Development and production portfolio with regulatory affairs.

• DLLD: Modifying parameters for Deep Learning for Lesion Distortion (DLLD).